Insmed, Inc. (INSM)

NASDAQ: INSM · IEX Real-Time Price · USD
21.54
-0.33 (-1.51%)
Sep 30, 2022 4:00 PM EDT - Market closed
-1.51%
Market Cap 2.58B
Revenue (ttm) 221.21M
Net Income (ttm) -415.96M
Shares Out 119.98M
EPS (ttm) -3.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 540,717
Open 21.88
Previous Close 21.87
Day's Range 21.48 - 22.47
52-Week Range 16.41 - 34.44
Beta 1.83
Analysts Buy
Price Target 50.09 (+132.5%)
Earnings Date Oct 26, 2022

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a tr... [Read more...]

Industry Biotechnology
IPO Date Jun 1, 2000
CEO William Lewis
Employees 613
Stock Exchange NASDAQ
Ticker Symbol INSM
Full Company Profile

Financial Performance

In 2021, Insmed's revenue was $188.46 million, an increase of 14.63% compared to the previous year's $164.41 million. Losses were -$434.65 million, 47.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for INSM stock is "Buy." The 12-month stock price forecast is 50.09, which is an increase of 132.54% from the latest price.

Price Target
$50.09
(132.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , Sept. 7, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...

3 weeks ago - PRNewsWire

Insmed To Present at Two September Conferences

BRIDGEWATER, N.J. , Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

3 weeks ago - PRNewsWire

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update

--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch --...

1 month ago - PRNewsWire

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022

BRIDGEWATER, N.J. , July 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

2 months ago - PRNewsWire

Insmed Names Drayton Wise Chief Commercial Officer

BRIDGEWATER, N.J. , May 23, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

4 months ago - PRNewsWire

Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference

—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Init...

4 months ago - PRNewsWire

Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference

BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

4 months ago - PRNewsWire

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update

--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million-- --Seven Clinical Trials Underway; Enrollment ...

4 months ago - PRNewsWire

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

BRIDGEWATER, N.J. , April 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...

5 months ago - PRNewsWire

Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference

--Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE® (amikacin liposome inhalation suspension) to be Presented in Poster Discussion Session-- --Analysi...

6 months ago - PRNewsWire

Insmed To Present at the Cowen 42nd Annual Health Care Conference

BRIDGEWATER, N.J. , March 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...

6 months ago - PRNewsWire

Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -6.74% and 10.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

7 months ago - PRNewsWire

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference

BRIDGEWATER, N.J., Feb. 10, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

7 months ago - PRNewsWire

Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipelin...

BRIDGEWATER, N.J., Jan. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

8 months ago - PRNewsWire

Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

8 months ago - PRNewsWire

Insmed To Participate in Three November Conferences

BRIDGEWATER, N.J., Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

10 months ago - PRNewsWire

New Strong Sell Stocks for October 29th

IBIO, POST, INSM, DVA, and BSET have been added to the Zacks Rank #5 (Strong Sell) List on October 29, 2021.

Other symbols: BSETDVAIBIOPOST
11 months ago - Zacks Investment Research

Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List

BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

11 months ago - PRNewsWire

Insmed (INSM) Reports Q3 Loss, Lags Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -15.66% and -2.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research